Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Suvratoxumab - Aridis Pharmaceuticals/Biosynexus/GlaxoSmithKline/Regeneron Pharmaceuticals

Next Previous
Drug Profile

Suvratoxumab - Aridis Pharmaceuticals/Biosynexus/GlaxoSmithKline/Regeneron Pharmaceuticals

Alternative Names: AR-320; human IgG1 mAb; MEDI-4893; Suvratoxumab - AstraZeneca

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosynexus; GlaxoSmithKline; Regeneron Pharmaceuticals
  • Developer Aridis Pharmaceuticals; AstraZeneca
  • Class Anti-infectives; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Staphylococcal infections; Ventilator associated pneumonia

Most Recent Events

  • 20 Dec 2024 Suvratoxumab is available for licensing as of 20 Dec 2024. https://www.aridispharma.com/
  • 03 Nov 2023 Suspended - Phase-II for Ventilator-associated-pneumonia (Prevention) in USA, Czech Republic, Switzerland, United Kingdom, Hungary, Germany (IV)
  • 03 Nov 2023 Suspended - Phase-III for Staphylococcal infections (Prevention) (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top